{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-019471","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.222418+00:00","generated_at":"2026-05-19T22:48:34.606129+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Allarity Therapeutics partners with Indiana Biosciences Research Institute to study stenoparib's dual mechanism","bullets":["Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.","Stenoparib is a dual PARP1/2 and tankyrase1/2 inhibitor currently in Phase 2 trial for advanced ovarian cancer.","Research may support future marketing approval and potential expansion into colorectal cancer and SCLC combination trial.","No financial terms of the collaboration were disclosed in the press release."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-019471","json":"https://secwatch.observer/filing/0001437749-25-019471.json","markdown":"https://secwatch.observer/filing/0001437749-25-019471.md","text":"https://secwatch.observer/filing/0001437749-25-019471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925019471/0001437749-25-019471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925019471/allr20250604_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:48:34.606129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}